P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.

Bibliographic Details
Published in:	HemaSphere
Main Authors:	G. Garcia-Manero, S. Bart, J. K. McCloskey, P. Fenaux, D. Selleslag, G. Reda, D. Valcárcel, V. Santini, J. Mayer, B. Xicoy, H. Yamaguchi, M. Lübbert, Y. Miyazaki, H. Keer, Y. Hao, M. Azab, H. Döhner
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845956.26644.d0

Similar Items

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
by: Robert Brown, et al.
Published: (2022-06-01)

Restoration and functional analysis of the SGI1 resolution system – SGI1 multimers are eliminated by the reactivated resolution
by: Alexandra Veress, et al.
Published: (2025-07-01)

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
by: Marie Sébert, et al.
Published: (2019-08-01)

P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)
by: C. D. DiNardo, et al.
Published: (2022-06-01)

P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
by: Guillermo Garcia-Manero, et al.
Published: (2023-08-01)

P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL
by: P. Fenaux, et al.
Published: (2022-06-01)

Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas
by: Emad Darvishi, et al.
Published: (2020-07-01)

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system
by: Thomas Prebet, et al.
Published: (2016-10-01)

P743: THE PIVOTAL ROLE OF GLUTAMINOLYSIS IN MYELODYSPLASTIC SYNDROME (MDS): A NOVEL STRATEGY FOR THE TARGETED THERAPY OF MDS
by: S. Okabe, et al.
Published: (2022-06-01)

On Thermal Expansion and Density of CGI and SGI Cast Irons
by: Taishi Matsushita, et al.
Published: (2015-06-01)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
by: Fabio Efficace, et al.
Published: (2024-05-01)

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
by: Amy E. DeZern, et al.
Published: (2025-08-01)

Superior Cloning Performance with SGI-DNA Gibson Assembly® kits
by: Christine Chen
Published: (2016-03-01)

Synthetic Genetic Interaction (CRISPR-SGI) Profiling in Caenorhabditis elegans
by: John Calarco, et al.
Published: (2018-03-01)

Deciphering the QR Code of the CRISPR-Cas9 System: Synergy between Gln768 (Q) and Arg976 (R)
by: Vangelis Daskalakis
Published: (2022-09-01)

Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects
by: Xuefeng Li, et al.
Published: (2025-05-01)

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
by: G. Garcia-Manero, et al.
Published: (2024-01-01)

Stemness genes and miR-1247-3p expression associate with clinicopathological parameters and prognosis in lung adenocarcinoma.
by: Shiwani Limbu, et al.
Published: (2023-01-01)

Merkel cell carcinoma cells proliferation is inhibited by the DNA methyltransferases inhibitor guadecitabine via methylome modulation
by: J.C. Rotondo, et al.
Published: (2024-01-01)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
by: Theo de Witte, et al.
Published: (2020-09-01)

An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
by: Tariq I. Mughal, et al.
Published: (2015-09-01)

Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group
by: Mohamed Amine Bekadja, et al.
Published: (2023-04-01)

THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (t-MDS) IN CHILDHOOD: THE EXPERIENCE OF THE HELLENIC STUDY GROUP FOR MDS/JMML/SAA, MEMBER OF THE EWOG-MDS/SAA WORKING GROUP
by: Loizos Petrikkos, et al.
Published: (2023-12-01)

Improving MDS Risk Assessment: The Role of Monocytopenia and Lymphocytopenia Beyond IPSS-R
by: Marijana Virijevic, et al.
Published: (2025-09-01)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
by: Josephine Lucero, et al.
Published: (2023-06-01)

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
by: Daniel Karel, et al.
Published: (2024-04-01)

Cytogenetic study of Brazilian patients with myelodysplastic syndrome (MDS)
by: Tamara Borgonovo, et al.
Published: (2005-12-01)

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
by: Cristina A. Tentori, et al.
Published: (2024-05-01)

Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center
by: Betül Oran, et al.
Published: (2025-07-01)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
by: A. DeZern, et al.
Published: (2022-06-01)

S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
by: Rami S. Komrokji, et al.
Published: (2023-08-01)

P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY
by: F. Schulz, et al.
Published: (2022-06-01)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
by: Sabine Blum, et al.
Published: (2021-09-01)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
by: Fieke W. Hoff, et al.
Published: (2023-02-01)

SGI-YOLOv9: an effective method for crucial components detection in the power distribution network
by: Mianfang Yang, et al.
Published: (2024-12-01)

Metoda TLM oraz wskaźnik SGI jako wyznaczniki suszy w wodach gruntowych
by: Justyna Kubicz
Published: (2018-03-01)

A molecular dynamics protocol for rapid prediction of EGFR overactivation and its application to the rare mutations S768I, S768N, D761N
by: Julian Behn, et al.
Published: (2025-01-01)

Real‐world, multi‐omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS)
by: Giulia Maggioni, et al.
Published: (2026-06-01)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
by: Amer M. Zeidan, et al.
Published: (2023-08-01)

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
by: Guangrui Li, et al.
Published: (2023-10-01)